Oxford BioMedica develops strategic development plan with the commercialisation of TroVax
Oxfordshire Bioscience Network (OBN), organisers of the forth coming Bio Trinity 2008 conference, has confirmed Peter Nolan, SVP Commercial Development at Oxford BioMedica as a lead speaker on this years programme. Mr Nolan will discuss the company's partnership with sanofi-aventis to develop and commercialise TroVax(r) for the treatment and prevention of a number of cancer indications. This follows the announcement that the TRIST trial successfully completed patient enrolment.
TroVax(r) is Oxford BioMedica's lead cancer immunotherapy. Based on the broad distribution of the 5T4 tumour antigen, TroVax(r) has potential application in a wide range of solid tumours, including renal, colorectal, lung, breast and prostate cancer. Earlier this month Oxford BioMedica announced that it has successfully completed patient enrolment in the Phase III TRIST study. Over 690 patients have been randomised to-date and a sufficient number of additional patients are being screened for inclusion such that the total enrolment is expected to slightly exceed the target of 700 patients. Over 100 sites in the USA, European Union and Eastern Europe have recruited patients into the trial. The trial started in November 2006; recruitment has been completed on schedule and final results from the study are anticipated in the first half of 2009.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.